Webbläsaren som du använder stöds inte av denna webbplats. Alla versioner av Internet Explorer stöds inte längre, av oss eller Microsoft (läs mer här: * https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Var god och använd en modern webbläsare för att ta del av denna webbplats, som t.ex. nyaste versioner av Edge, Chrome, Firefox eller Safari osv.

Clinical and Experimental Approach to the Benefits and Risks of Laser Treatment for Diabetic Macular Edema

Författare

Summary, in English

Diabetic retinopathy is an ophthalmic complication of diabetes that currently affects 93 million people worldwide. Diabetic macular edema is a subtype of diabetic retinopathy that is characterized by leaking blood vessels in the central part of the retina, and it is a major cause of vision loss in individuals with diabetes. Screening for retinopathy is performed at regular intervals to identify subjects in need of treatment. In Sweden, the recommended screening interval for type 2 diabetic subjects with no diabetic retinopathy is 3 years. Laser treatment for diabetic macular edema has been used for decades, but studies have reported conflicting results regarding possible clinical complications following such therapy. Furthermore, the molecular events involved in the clinical benefits of laser treatment have not been fully explored.



To determine the safety of the current screening interval, the 3-year incidence of diabetic retinopathy and macular edema was monitored in type 2 diabetic subjects with no retinopathy (Study I). To identify the long-term effects of laser treatment, the retinal sensitivity in 29 consecutively recruited subjects with diabetic macular edema was assessed by visual fields before and after laser treatment every 6 months during a period of 2 years (Study II). To investigate the cellular and molecular events that may be involved in the clinical benefits of laser treatment, a model of in vitro laser coagulation of the retinal pigment epithelium was established and used to evaluate cell death and cell repair (Study III). The same model was also used to explore the effects of laser treatment on mRNA and protein levels by analysis of microarray and proteomics data (Study IV).



Study I demonstrated a very low incidence of sight-threatening diabetic retinopathy, which supports the current use of a 3-year retinal screening interval for the subgroup in question. Study II showed no change in retinal sensitivity following laser treatment for diabetic macular edema during the 2-year follow-up compared to baseline. Study III revealed that laser-induced damage involved both necrosis and apoptosis, and the repair process entailed both proliferation and migration. In study IV, the downregulation of the protein Carbonic anhydrase 9 and the upregulation of heat shock proteins 1A and 1B were the most interesting findings and might explain some of the beneficial effects of laser treatment for diabetic macular edema.

Publiceringsår

2016

Språk

Engelska

Publikation/Tidskrift/Serie

Lund University Faculty of Medicine Doctoral Dissertation Series

Volym

2016:13

Dokumenttyp

Doktorsavhandling

Förlag

Ophthalmology, Lund University

Ämne

  • Ophthalmology

Nyckelord

  • Diabetic macular edema
  • laser treatment
  • retinal pigment epithelium
  • ARPE-19
  • microarray
  • proteomics

Status

Published

Forskningsgrupp

  • Ophthalmology (Malmö)

Handledare

ISBN/ISSN/Övrigt

  • ISSN: 1652-8220
  • ISBN: 978-91-7619-239-9

Försvarsdatum

15 april 2016

Försvarstid

09:15

Försvarsplats

Lilla aulan, Jan Waldenströms gata 5, Malmö

Opponent

  • Anders Kvanta (Professor)